AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
Jun 3, 2016
31289_dirs_2016-06-03_2f234b70-e7c1-43e2-96ab-5889f4731ce9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-05-20
Reporting Person: KOZARICH JOHN W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-05-20 | Common Stock | G | 350.0 | — | Disposed | 43361 | Direct |
| 2016-06-01 | Common Stock | S | 900.0 | $117.19 | Disposed | 43083 | Direct |
| 2016-06-01 | Common Stock | S | 100.0 | $119.48 | Disposed | 42983 | Direct |
Footnotes
F1: Charitable gift to a third party.
F2: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.77 to $117.71, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.